At the end of 2015 there were almost 600 new oncology-related molecules in late-stage development, so it is no surprise that two-years on, the number of therapeutic options in cancer care is growin
In the first of two articles, Theano Anastasopoulou uses behavioural economics to understand and investigate how physicians make decisions and thereby improve the take-up of new medicines.
BeiGene has claimed a second EU approval for PD-1 inhibitor tislelizumab in non-small cell lung cancer (NSCLC), opening the door to the first launches of the drug outside
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.